Background Progressive supranuclear palsy and Parkinson's disease have characteristic clinical and neuropathologic profiles, but also share overlapping clinical features. This study aimed to ...

FNP-223 is currently being investigated in a phase 2 trial evaluating the treatment in adults with possible or probable PSP-Richardson syndrome.

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are both closely related sporadic parkinsonian disorders with tau pathology that share many clinical features, such as ...

Find all the latest on progressive supranuclear palsy at Medical Xpress. Your go-to source for news, research, and medical breakthroughs.

LONDON, GB / ACCESS Newswire / April 28, 2025 / The Progressive Supranuclear Palsy (PSP) Trial Platform (PTP), led by Drs. Adam Boxer (University of California, San Francisco [UCSF]), Irene Litvan ...

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens ACCESS Newswire. April 28, 2025 9:05 AM.

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens ACCESS Newswire. April 28, 2025 10:05 AM.

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens ACCESS Newswire. April 28, 2025 7:05 AM.

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens ACCESS Newswire. April 28, 2025 10:05 AM.

Progressive Supranuclear Palsy Phase 2 Platform Clinical Trial Announces the Selection of AADvac1 and AZP2006 for its First Two Regimens ACCESS Newswire. April 28, 2025 10:05 AM.